Prosecution Insights
Last updated: October 27, 2026
Application No. 17/223,756

SPRAY DRIED NICOTINE FOR INCLUSION IN ORAL PRODUCTS

Non-Final OA §103
Filed
Apr 06, 2021
Examiner
TRAN, SUSAN T
Art Unit
1615
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Altria Client Services LLC
OA Round
5 (Non-Final)
63%
Grant Probability
Moderate
5-6
OA Rounds
0m
Est. Remaining
98%
With Interview

Examiner Intelligence

Grants 63% of resolved cases
63%
Career Allowance Rate
657 granted / 1043 resolved
+3.0% vs TC avg
Strong +35% interview lift
Without
With
+34.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 1m
Avg Prosecution
27 currently pending
Career history
1088
Total Applications
across all art units

Statute-Specific Performance

§101
0.9%
-39.1% vs TC avg
§103
40.9%
+0.9% vs TC avg
§102
20.6%
-19.4% vs TC avg
§112
21.9%
-18.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1043 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after allowance or after an Office action under Ex Parte Quayle, 25 USPQ 74, 453 O.G. 213 (Comm'r Pat. 1935). Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, prosecution in this application has been reopened pursuant to 37 CFR 1.114. Applicant's submission filed on 06/03/2024 has been entered. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 17, 18 and 20-27 are rejected under 35 U.S.C. 103 as being unpatentable over Nyambura et al. US 2021/0386666 A1, in view of Piskorz US 20120042886. Nyambura teaches a method for the preparation of an organic-in-aqueous liquid emulsion for spray drying so as to form the spray dried particles as defined herein, said method comprising (a) providing (i) an aqueous liquid composition comprising an alginate oligomer as defined herein and an aqueous liquid composition comprising an anti-adherent compound as defined herein or (ii) an aqueous liquid composition comprising an alginate oligomer as defined herein and an anti-adherent compound as defined herein, (b) providing an organic liquid composition comprising a phospholipid as defined herein, (c) combining a volume of the organic liquid composition with a volume of the aqueous liquid compositions of (i) or the aqueous liquid composition of (ii), wherein the volume of the organic liquid composition is smaller than the total volume of the aqueous liquid composition with which it is combined, and (d) homogenising the combination so formed at any time during step (c) or on upon completion of step (c) to form the organic-in-aqueous liquid emulsion for spray drying so as to form the spray dried particles as defined herein. See paragraphs 0126-0132. The aqueous liquid composition comprising said alginate oligomer and/or said anti-adherent compound may be formed upon the dissolution of the alginate oligomer and/or anti-adherent compound in any pharmaceutically acceptable aqueous liquid. Conveniently this liquid will be water, preferably substantially pure water, e.g. distilled water or filtered water, however, some additional compounds (e.g. salts, organic acids, buffers) may also be present so long as such compounds are present in amounts that will not result in spray dried particles containing more than 10% of said compounds and do not interfere with particle formation. The method of the invention may include further steps of preparing the aqueous liquid composition(s). These steps may involve dissolving the alginate oligomer and/or the anti-adherent compound in the aqueous liquid at the same time or sequentially, or adding one of those two ingredients to an aqueous liquid already containing the other. See paragraph 0143. Homogenization can be achieved by any convenient means, e.g. by mechanical means and/or ultrasonic means, for example by high shear mixing. Apparatus for performing such a homogenization (e.g. a homogenizer) is widely known and available in the art, for example a Silverson homogenizer, which may be operated at 10,000 rpm. Homogenization is preferably performed for such time as a complete emulsion is formed to the naked eye. Homogenization may be performed as the two liquid phases are combined, or after all of the liquid phases have been combined. In other embodiments homogenization may begin once a part of each phase has been combined. See paragraph 0146 and Example 1. Nyambura does not expressly teach dissolving carrier to form a first solution and contacting with nicotine to form a second mixture in the first solution. Piskorz teaches a method for preparing nicotine particle comprises dissolving sugar and nicotine in a solvent such as water. The sugar and nicotine can be dissolved in solvent in any order to form a solution or solutions. The solutions are then homogenized and spray dried to form a nicotine particle having particle diameter of about 5 µm. See paragraphs 0041 and 0044-0048. Spray drying condition and temperatures is found in paragraphs 0064-0065. Thus, it would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made to optimize the teaching of Nyambura in view of the method in the Piskorz reference with the expectation to obtain a nicotine-containing powder having uniform particle size useful in pharmaceutical art. This is because Piskorz teaches dissolving sugar and nicotine to form two different solutions or in any order is known in the art. Correspondence Any inquiry concerning this communication or earlier communications from the examiner should be directed to SUSAN T TRAN whose telephone number is (571)272-0606. The examiner can normally be reached Monday-Friday, 8:30 am-5:30 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, ROBERT A. WAX can be reached on 571-272-0623. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SUSAN T TRAN/Primary Examiner, Art Unit 1615
Read full office action

Prosecution Timeline

Show 32 earlier events
Dec 11, 2025
Response after Non-Final Action
Feb 19, 2026
Request for Continued Examination
Feb 24, 2026
Response after Non-Final Action
Apr 29, 2026
Request for Continued Examination
May 04, 2026
Response after Non-Final Action
Jun 03, 2026
Request for Continued Examination
Jun 08, 2026
Response after Non-Final Action
Sep 30, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12766087
SUNSCREEN COMPOSITIONS AND METHOD OF USE THEREOF
4y 11m to grant Granted Oct 20, 2026
Patent 12767924
FORMULATIONS OF MICROENCAPSULATED MICROBIAL CULTURE WITH HIGH STORAGE STABILITY
2y 6m to grant Granted Oct 20, 2026
Patent 12758537
INCREASED E-CADHERIN EXPRESSION OR ACTIVITY FOR THE TREATMENT OF INFLAMMATORY DISEASES
5y 3m to grant Granted Oct 13, 2026
Patent 12746266
ESSENTIAL OIL COMPOSITIONS AND APPLICATIONS UTILIZING ESSENTIAL OILS
4y 5m to grant Granted Sep 29, 2026
Patent 12746232
PATCH FOR ALLEVIATING OR TREATING SYMPTOMS OF NEURODEGENERATIVE DISEASE
3y 7m to grant Granted Sep 29, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
63%
Grant Probability
98%
With Interview (+34.8%)
3y 1m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 1043 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month